SNYR (Synergy CHC Corp) Gross Profit Margin

Corporate emblem and logo of Synergy CHC (SNYR)

Slowing sales growth driven by online competition is weakening the cash flow of Synergy CHC Corp (SNYR). The gross margin metric illustrates the current trend of efficiency recovery, where 65.40 characterizes this valuation parameter. Margin resilience is supported by the automation of warehouse chains, while the implementation of software algorithms in inventory management and the robotization of centers minimize personnel costs.

SNYR (Synergy CHC Corp.) Gross Margin history from 10/24/2024 to 10/03/2026

Comprehensive metric breakdowns and analytics for Synergy CHC Corporation (SNYR)

- business market valuation indicators:
Fundamental valuation:SNYR, Synergy CHC Corp
Signature product of Synergy CHC Corp.

Synergy CHC Corp (SNYR) effectively curbs competition within the stringent FDA regulatory environment through its diversified brand portfolio and resilient retail positions. By analyzing the gross margin distribution, recorded at 65.40, an investor can see the revenue share net of direct production costs, allowing for the immediate identification of abnormal cost spikes and a real-time assessment of the business's fundamental ability to generate profit.

Direct competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Profitability Invizyne (EXOZ)|ORMP - Gross Profit Margin|Gross Margin ENTX (Entera Bio)|Gross Sales Margin MindWalk Therapeutics|ABVC: Return on Gross Profit|CPIX - Gross Margin|QNTM (Quantum BioPharma) - Return on Gross Profit|Gross Profitability Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Gross Margin|Gross Margin ranitherapeutics.com|Gross Profitability Rallybio Corp. (RLYB)|LEXX - Gross Profit Margin|Gross Margin PULM (pulmatrix.com)|Gross Profit Ratio PTHL (Pheton)|APM - Gross Profitability|Return on Sales by Gross Profit Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Gross Profitability|TNF Pharma (TNFA) - Gross Margin|YCBD (cbdmd.com) - Gross Margin|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin